Novel interaction between Alzheimer’s disease-related protein presenilin 1 and glutamate transporter 1
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Novel interaction between Alzheimer’s disease-related protein presenilin 1 and glutamate transporter 1 ; volume:8 ; number:1 ; day:7 ; month:6 ; year:2018 ; pages:1-9 ; date:12.2018
Scientific reports ; 8, Heft 1 (7.6.2018), 1-9, 12.2018
- Urheber
- Beteiligte Personen und Organisationen
-
Maesako, Masato
Meier, Joshua
Berezovska, Oksana
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-26888-2
- URN
-
urn:nbn:de:101:1-2018080923374837236413
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.0011, 06:26 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zoltowska, Katarzyna Marta
- Maesako, Masato
- Meier, Joshua
- Berezovska, Oksana
- SpringerLink (Online service)
Ähnliche Objekte (12)
Function and dysfunction of presenilin in Alzheimer’s disease
Identifying Alzheimer’s disease-related proteins by LRRGD
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Selective ferroptosis vulnerability due to familial Alzheimer’s disease presenilin mutations
Alzheimer’s disease-related transcriptional sex differences in myeloid cells
Presenilin E318G variant and Alzheimer’s disease risk: the Cache County study
Zinc transporters in Alzheimer’s disease
Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration
PS1/gamma-secretase acts as rogue chaperone of glutamate transporter EAAT2/GLT-1 in Alzheimer’s disease
Identification and validation of Alzheimer’s disease-related metabolic brain pattern in biomarker confirmed Alzheimer’s dementia patients
Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer’s disease
Methylomic profiling in trisomy 21 identifies cognition- and Alzheimer’s disease-related dysregulation
Function and dysfunction of presenilin in Alzheimer’s disease
Identifying Alzheimer’s disease-related proteins by LRRGD
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Selective ferroptosis vulnerability due to familial Alzheimer’s disease presenilin mutations
Alzheimer’s disease-related transcriptional sex differences in myeloid cells
Presenilin E318G variant and Alzheimer’s disease risk: the Cache County study
Zinc transporters in Alzheimer’s disease
Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration
PS1/gamma-secretase acts as rogue chaperone of glutamate transporter EAAT2/GLT-1 in Alzheimer’s disease
Identification and validation of Alzheimer’s disease-related metabolic brain pattern in biomarker confirmed Alzheimer’s dementia patients
Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer’s disease
Methylomic profiling in trisomy 21 identifies cognition- and Alzheimer’s disease-related dysregulation
Function and dysfunction of presenilin in Alzheimer’s disease
Identifying Alzheimer’s disease-related proteins by LRRGD
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Selective ferroptosis vulnerability due to familial Alzheimer’s disease presenilin mutations
Alzheimer’s disease-related transcriptional sex differences in myeloid cells
Presenilin E318G variant and Alzheimer’s disease risk: the Cache County study
Zinc transporters in Alzheimer’s disease
Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration
PS1/gamma-secretase acts as rogue chaperone of glutamate transporter EAAT2/GLT-1 in Alzheimer’s disease
Identification and validation of Alzheimer’s disease-related metabolic brain pattern in biomarker confirmed Alzheimer’s dementia patients
Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer’s disease